Got it, thanks. I'm trying hard to remember why was VVUS confident about that JNJ '537 patent. Think there was a paper published a few years before the patent filing which talked about the use of topiramate in obesity.
Who knows if it's naive or bs, but vvus for quite some time have indicated this is all not a worry as their top management are personal friends of jnj top management. Buyout, jv, reasonable patent license with jnj to come?
Market Data 
Markets 
AI
